Stock PLX PROTALIX BIOTHERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Protalix BioTherapeutics, Inc.

Equities

PLX

US74365A3095

Real-time Estimate Cboe BZX
Other stock markets
 10:25:26 29/04/2024 pm IST 		5-day change 1st Jan Change
1.225 USD +6.52% Intraday chart for Protalix BioTherapeutics, Inc. +2.97% -31.74%
14/03 Transcript : Protalix BioTherapeutics, Inc., 2023 Earnings Call, Mar 14, 2024
14/03 Protalix BioTherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • For the past twelve months, EPS forecast has been revised upwards.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
PROTALIX BIOTHERAPEUTICS, INC. Stock Protalix BioTherapeutics, Inc.
-31.74% 84.01M -
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+2.67% 42.75B
B
LONZA GROUP AG Stock Lonza Group AG
+47.70% 41.61B
A
MODERNA, INC. Stock Moderna, Inc.
+12.26% 41.34B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-8.83% 26.59B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.39% 25.49B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.52% 18.12B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+31.20% 12.24B
C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.48% 11.76B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+9.05% 11B
B+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PLX Stock
  4. Ratings Protalix BioTherapeutics, Inc.